| Mapping to estimate health-state utility from non–preference-based outcome measures: an ISPOR good practices for outcomes research task force report AJ Wailoo, M Hernandez-Alava, A Manca, A Mejia, J Ray, B Crawford, ... Value in Health 20 (1), 18-27, 2017 | 180 | 2017 |
| Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain JA Ray, WJ Valentine, K Secnik, AK Oglesby, A Cordony, A Gordois, ... Current medical research and opinion 21 (10), 1617-1629, 2005 | 164 | 2005 |
| Cost‐effectiveness of diabetes case management for low‐income populations TP Gilmer, S Roze, WJ Valentine, K Emy‐Albrecht, JA Ray, D Cobden, ... Health services research 42 (5), 1943-1959, 2007 | 106 | 2007 |
| Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes JA Ray, KS Boye, N Yurgin, WJ Valentine, S Roze, J McKendrick, ... Current medical research and opinion 23 (3), 609-622, 2007 | 77 | 2007 |
| Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH WJ Valentine, AJ Palmer, KM Erny-Albrecht, JA Ray, D Cobden, V Foos, ... Advances in therapy 23, 191-207, 2006 | 66 | 2006 |
| Counting the costs of overweight and obesity: modeling clinical and cost outcomes DMD Tucker, AJ Palmer, WJ Valentine, S Roze, JA Ray Current medical research and opinion 22 (3), 575-586, 2006 | 55 | 2006 |
| Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the … ME Minshall, S Roze, AJ Palmer, WJ Valentine, V Foos, J Ray, C Graham Clinical therapeutics 27 (6), 940-950, 2005 | 55 | 2005 |
| Insulin therapy in type 2 diabetes patients failing oral agents: cost‐effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US JA Ray, WJ Valentine, S Roze, L Nicklasson, D Cobden, P Raskin, ... Diabetes, Obesity and Metabolism 9 (1), 103-113, 2007 | 49 | 2007 |
| An economic assessment of analogue basal–bolus insulin versus human basal–bolus insulin in subjects with type 1 diabetes in the UK AJ Palmer, WJ Valentine, JA Ray, V Foos, F Lurati, I Smith, M Lammert, ... Current medical research and opinion 23 (4), 895-901, 2007 | 45 | 2007 |
| An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK JA Ray, E Carr, G Lewis, R Marcus Value in health 13 (4), 346-357, 2010 | 43 | 2010 |
| Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States WJ Valentine, KM Erny-Albrecht, JA Ray, S Roze, D Cobden, AJ Palmer Advances in therapy 24, 273-290, 2007 | 39 | 2007 |
| Mixture cure models in oncology: a tutorial and practical guidance F Felizzi, N Paracha, J Pöhlmann, J Ray PharmacoEconomics-open 5, 143-155, 2021 | 36 | 2021 |
| Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long‐term health economic implications in a Swedish setting G Goodall, JH Jendle, WJ Valentine, V Munro, AB Brandt, JA Ray, S Roze, ... International journal of clinical practice 62 (6), 869-876, 2008 | 34 | 2008 |
| Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer A Vergnenègre, JA Ray, C Chouaid, F Grossi, HG Bischoff, DF Heigener, ... ClinicoEconomics and Outcomes Research, 31-37, 2012 | 32 | 2012 |
| Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe S Walleser, J Ray, H Bischoff, A Vergnenègre, H Rosery, C Chouaid, ... ClinicoEconomics and Outcomes Research, 269-275, 2012 | 28 | 2012 |
| CUSTO-EFECTIVIDADE DE TRASTUZUMAB A Macedo, I Monteiro, S Andrade, A Cirrincione, J Ray Acta Med Port 23, 475-482, 2010 | 27 | 2010 |
| The value of innovation under value-based pricing SG Moreno, JA Ray Journal of market access & health policy 4 (1), 30754, 2016 | 26 | 2016 |
| Cost-effectiveness model for chemoimmunotherapy options in patients with previously untreated chronic lymphocytic leukemia unsuitable for full-dose fludarabine-based therapy U Becker, AH Briggs, SG Moreno, JA Ray, P Ngo, K Samanta Value in Health 19 (4), 374-382, 2016 | 25 | 2016 |
| Assessment of alectinib vs ceritinib in ALK-positive non–small cell lung cancer in phase 2 trials and in real-world data S Wilkinson, A Gupta, N Scheuer, E Mackay, P Arora, K Thorlund, ... JAMA Network Open 4 (10), e2126306-e2126306, 2021 | 18 | 2021 |
| Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA JA Ray, R Borker, B Barber, WJ Valentine, V Belozeroff, AJ Palmer Value in Health 11 (5), 800-808, 2008 | 18 | 2008 |
